Geron

GERN

Market cap $753M

Geron reported Q3'25 Rytelo revenues of $47.2M, down from $49M in Q2, with no underlying increase in demand reported. Despite efforts to boost Rytelo's use in first and second-line therapy (now 36%, up from 30%), revenue growth remains elusive for GERN. Recent leadership changes include the departure of COO Andrew Grethlein and CCO Jim Ziegler, with Ahmed ElNawawi stepping in as CCO.

Geron Corporation ( GERN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian - CEO, President & Director Joseph Eid - Executive VP of Research & Development and Chief Medical Officer Michelle Robertson - Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Ahmed ElNawawi Conference Call Participants Tara Bancroft - TD Cowen, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Presentation Operator Hello, and welcome to the Geron Corporation Third Quarter 2025 Earnings Call.

Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights. "The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action and the potential to significantly impact the treatment paradigm. There is work ahead of us to fully maximize the.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2025 Healthcare Conference Fireside chat on Tuesday, November 11 at 11:40 AM ET in New York, NY 8th Annual Evercore Healthcare Conference Fireside chat on Tuesday, December 2 at 11:15 A.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts – one oral and four poster presentations – have been accepted for presentation at the 67th American Society of Hematology (ASH) 2025 Annual Meeting, to be held December 6-9, 2025 in Orlando, FL. The data feature new clinical and translational analyses of RYTELO (imetelstat) across l.

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A li.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder of  Geron securities between February 28, 2024 and February 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Geron Corporation (GERN) is rated BUY due to strong early RYTELO sales, robust financials, and an undervalued stock price near 52-week lows. RYTELO, recently FDA-approved for lower-risk MDS, is driving revenue growth and has significant peak sales potential, with further pipeline expansion underway. A strengthened executive team and global expansion plans position GERN for sustainable growth, despite competition from established therapies like Reblozyl.